Health

Medtelligence launches educational program emphasizing major improvements in lipid management for patients with diabetes

Leave a comment


Medtelligence, a GLC Company

Medtelligence


FORT WASHINGTON, Pa. (PRWEB)

Medtelligence, a leading provider of cardiovascular disease clinical education, today announced the launch of a scientific program featuring topics in omega-3 fatty acids and atherosclerotic cardiovascular disease (ASCVD) risk reduction in patients with diabetes.

Chaired by Dr. Yehuda Handelsman (Tarzana, Ca), the 2-hour recorded session features expert faculty, including Drs. Om Ganda (Boson, MA), Paul Rosenblit (Huntington Beach, CA), Jorge Plutzky (Boston, MA) and Deepak L. Bhatt (Boston, MA). The original program was presented on June 13, 2020, during the 80th Scientific Sessions Meeting of the American Diabetes Association (conducted virtually) and is now available on-demand to clinicians worldwide.

During the two-hour session, faculty addressed topics on pressing clinical issues in lipid biology and therapeutics, including new guideline-recommended therapies beyond statins. Topics included an update on lipid biomarkers (P. Rosenblit), high-risk patients (O. Ganda), dyslipidemia therapies in 2020 (Y. Handelsman), and the biology of omega-3 fatty acids (J. Plutzky).

Dr. Bhatt (Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart and Vascular Center, and Professor of Medicine, Harvard Medical School), presented late-breaking data from REDUCE-IT Diabetes. “Compared with placebo, icosapent ethyl 4g/day significantly reduced both first and total primary endpoint events in patients with diabetes at baseline by 23% and 24%, respectively,” said Bhatt. “These data highlight the substantial impact of icosapent ethyl on the underlying atherothrombotic burden in the at-risk REDUCE-IT population, both in those with but also in those without diabetes mellitus.”

Dr. Handelsman presented an overview of professional society guidelines, many of which were recently updated.

“We are very excited to offer this program to the clinician population across the globe,” said Medtelligence President Kathleen Wickman, BSN. “These trial data truly show a shift in ways to manage patients with diabetes to achieve optimal CVD outcomes, and we are working to bring that to the attention of clinicians who treat ASCVD.”

This activity was supported through an educational grant from Amarin Pharma, Inc.

About Medtelligence

Medtelligence is an industry leader in cardiovascular disease medical education, offering digital education and live meetings across the globe. Medtelligence is a member of the Global Learning Collaborative (GLC), which also includes Omnia Education, Prova Education, and the Academy for Global Interprofessional Learning & Education (AGILE). GLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. More information on Medtelligence is available at http://www.medtelligence.net.

Share article on social media or email:

Leave a Reply